ETV4 Is Necessary for Estrogen Signaling and Growth in Endometrial Cancer Cells Adriana C

Total Page:16

File Type:pdf, Size:1020Kb

ETV4 Is Necessary for Estrogen Signaling and Growth in Endometrial Cancer Cells Adriana C Published OnlineFirst February 11, 2020; DOI: 10.1158/0008-5472.CAN-19-1382 CANCER RESEARCH | GENOME AND EPIGENOME ETV4 Is Necessary for Estrogen Signaling and Growth in Endometrial Cancer Cells Adriana C. Rodriguez1,2, Jeffery M. Vahrenkamp1,2, Kristofer C. Berrett1,2, Kathleen A. Clark1,2, Katrin P. Guillen1,2, Sandra D. Scherer1,2, Chieh-Hsiang Yang2,3,4, Bryan E. Welm1,2,5, Margit M. Janat-Amsbury 3,4, Barbara J. Graves1,2,6, and Jason Gertz1,2 ABSTRACT ◥ Estrogen signaling through estrogen receptor alpha (ER) plays a factor in controlling the activity of ER and the growth of endometrial major role in endometrial cancer risk and progression, however, cancer cells. the molecular mechanisms underlying ER's regulatory role in endo- Graphical Abstract: http://cancerres.aacrjournals.org/content/ metrial cancer are poorly understood. In breast cancer cells, ER canres/80/6/1234/F1.large.jpg. genomic binding is enabled by FOXA1 and GATA3, but the transcription factors that control ER genomic binding in endome- Endometrial cancer cells trial cancer cells remain unknown. We previously identified ETV4 as ER Wild-type a candidate factor controlling ER genomic binding in endometrial cancer cells, and here we explore the functional importance of ETV4. Cytoplasm Homozygous deletion of ETV4, using CRISPR/Cas9, led to greatly reduced ER binding at the majority of loci normally bound by ER. Nucleus Consistent with the dramatic loss of ER binding, the gene expression response to estradiol was dampened for most genes. ETV4 con- ETV4 tributes to estrogen signaling in two distinct ways. ETV4 loss affects chromatin accessibility at some ER bound loci and impairs ER ETV4 -/- nuclear translocation. The diminished estrogen signaling upon ETV4 deletion led to decreased growth, particularly in 3D culture, Cytoplasm where hollow organoids were formed and in vivo in the context of estrogen-dependent growth. These results show that ETV4 plays an Nucleus Hollow organoid formation important role in estrogen signaling in endometrial cancer cells. Reduced in vivo growth Significance: Estrogen receptor alpha (ER) is a key oncogene in endometrial cancer. This study uncovers ETV4 as an important Loss of ETV4 diminishes estrogen signaling, which leads to decreased growth of endometrial cancer cells. Introduction the number of fertility cycles, and obesity, which leads to peripheral estrogen production, all indicate a central role for estrogen signaling Endometrial cancer is the fourth most common cancer among in endometrial cancer development (reviewed in ref. 3). Endome- women and the most common gynecologic cancer, leading to over trial cancer mutations in the ligand binding domain of ER (4, 5), 12,000 deaths in the United States each year (1). Type 1 endometrial which likely confer constitutive activity, implicate ER as the main cancer makes up 85% of cases, and the vast majority of these cases mediator of estrogen signaling in endometrial tumors. Endometrial express estrogen receptor a (ER), a steroid hormone receptor (2). cancer is most commonly treated by hysterectomy; however, pro- Risk factors such as unopposed estrogen therapy, tamoxifen treat- gestins, synthetic progesterone, serve as an effective alternative ment for breast cancer, lifetime exposure to estrogens as captured by treatment (6). Progestins bind to and activate progesterone recep- tor, which antagonizes the mitogenic effects of ER (7). These risk factors and treatment strategies for endometrial cancer point to ER 1Department of Oncological Sciences, University of Utah, Salt Lake City, Utah. as a key oncogene in the disease. 2 3 Huntsman Cancer Institute, University of Utah, Salt Lake City, Utah. Division of Although ER plays an important role in endometrial cancer, little is Gynecologic Oncology, Department of Obstetrics and Gynecology, University of understood about ER's molecular actions in endometrial cancer cells. Utah, Salt Lake City, Utah. 4Department of Bioengineering, University of Utah, Salt Lake City, Utah. 5Department of Surgery, University of Utah, Salt Lake City, Many of the molecular details concerning ER have come from Utah. 6Howard Hughes Medical Institute, Chevy Chase, Maryland. extensive work in breast cancer (8–15), where ER has a critical oncogenic role. These findings include regulatory cofactors that ER Note: Supplementary data for this article are available at Cancer Research – Online (http://cancerres.aacrjournals.org/). utilizes to regulate gene expression (16 18). In addition, FOXA1 and GATA3 have been shown to be necessary pioneer factors that maintain Corresponding Author: Jason Gertz, University of Utah, Huntsman Cancer accessible chromatin for ER in breast cancer cells (19–21). ER binds to Institute, 2000 Circle of Hope, Salt Lake City, UT 84112. Phone: 801-213-5662; – fi E-mail: [email protected] the genome in a cell type speci c manner with disparate binding between breast and endometrial cancer cells (14, 22); therefore, Cancer Res 2020;80:1234–45 different transcription factors are likely to control ER binding in doi: 10.1158/0008-5472.CAN-19-1382 endometrial cancer cells. In concordance with this idea, FOXA1 and Ó2020 American Association for Cancer Research. GATA3 exhibit low expression in endometrial tumors (4). As ER has a AACRJournals.org | 1234 Downloaded from cancerres.aacrjournals.org on September 25, 2021. © 2020 American Association for Cancer Research. Published OnlineFirst February 11, 2020; DOI: 10.1158/0008-5472.CAN-19-1382 ETV4 Is Crucial for Estrogen Signaling in Endometrial Cancer different set of genomic binding sites and FOXA1 only overlaps with were conducted following approved Institutional Animal Care and 8% of ER's binding sites in endometrial cancer cells and tumors, Use Committee protocols. In brief, endometrial cancer patient compared with 57% in breast cancer cells (14, 22), it is likely that specimens were collected in the operating room by the Bioreposi- different transcription factors are responsible for controlling ER's tory and Molecular Pathology Shared Resource and transported in genomic interactions in endometrial cancer cells. ice-cold RPMI-1640 medium (ATCC) to the lab. Each tissue In a previous study, we identified ETV4, an ETS factor, as playing a specimen was mechanically separated into multiple pieces using potential role in endometrial cancer–specific ER binding (14). De novo a sterile disposable scalpel (Andwin Scientific). A minimum of three motif discovery of ER binding sites specific to endometrial cancer cells 6- to 8-week-old, female nude mice (nu/nu; Jackson Laboratories) identified the ETS factor motif. Of the ETS factors, ETV4 is specifically were used for tumor implantation. Animals were anesthetized by expressed in the endometrial cancer cell line Ishikawa, as opposed to intraperitoneal injection of xylazine–ketamine mixture at a dose of the ER-positive breast cancer cell line T-47D. Chromatin immuno- 0.1 mg/kg and a subcutaneous analgesia, buprenophine (Reckitt precipitation sequencing (ChIP-seq) in Ishikawa cells revealed that Benckiser Pharmaceuticals), at a dose of 0.1 mg/kg. A longitudinal ETV4 overlaps with 45% of ER bound sites (14); however, the 1-cm incision was made in the lower midline of the abdominal wall functional importance of this overlap has not been tested. The to penetrate the skin and peritoneum and then the uterus was potential role of ETV4 in controlling ER binding in endometrial exposed. A 2-mm incision was made on one horn of the mouse cancer is an intriguing possibility, as other members of the ETS family uterus. Tumor fragment (4mm3) was implanted into the mouse have been shown to have pioneering capabilities for steroid hormone uterus under the microscope, and the incision was closed using 6-0 receptors. In prostate cancer, overexpression of ETV1, an ETS factor prolene suture (Ethicon). The peritoneum and abdominal wall were closely related to ETV4, has been shown to reprogram androgen sutured using 4-0 PERMA-HAND silk sutures and 4-0 polyglycolic receptor genome binding and associated transcription regulation, acid sutures (Ethicon), respectively, and then disinfected with leading to the formation of prostatic intraepithelial neoplasia (23), alcohol/iodine. The nude mice were not given supplemental estro- and contributing to more aggressive tumors (24). Similar effects have gen. E2 was monitored in the blood and found to be in the range of been shown for ERG, another ETS factor commonly overexpressed in 25 to 50 pmol/L; however, because the patient-derived xenografts prostate cancer (25). The mechanisms underlying these effects on (PDX)wereimplantedintheorthotopicsite,E2levelsmayhave androgen receptor are still unclear; however, a physical interaction has been higher in the tumor environment. Tumor size was measured been observed between ETV1 and androgen receptor (23). Though twice per week. Necropsy was performed once tumor size reached ETS factors in prostate cancer are being widely studied, the functional 2 cm in diameter. Clinical attributes can be found in Supplementary role of ETV4 in ER's genomic binding in endometrial cancer has not TableS1.Modelsareavailableuponrequest. been evaluated. In this study, we use CRISPR/Cas9 to knockout ETV4 in Ishikawa Generation of knockout lines cells in order to determine the importance of ETV4 in controlling ER Ishikawa cells were grown in a 6-well plate in full media and genomic binding. Despite having no effect on ER protein levels, ETV4 cotransfected with the PEA3 (alias for ETV4) CRISPR/Cas9 KO knockout led to greatly reduced ER binding, with the majority of sites plasmid (Santa Cruz, sc-422185) and the PEA3 HDR plasmid (Santa exhibiting a significant reduction in ChIP-seq signal. Consistent with Cruz, sc-422185-HDR) using Lipofectamine 3000. Cells were treated the reduction in ER binding, the transcriptional response to 17b- with puromycin at 1 mg/mL beginning 72 hours after transfection. estradiol (E2) was diminished due to ETV4 knockout. Chromatin RFP-positive single cells were sorted using fluorescence-activated cell accessibility was also reduced, but only at a subset of sites, suggesting sorting into each well of a 96-well plate. Screening for knockout clones a minimal pioneering role for ETV4 in endometrial cancer cells.
Recommended publications
  • Functions of the Mineralocorticoid Receptor in the Hippocampus By
    Functions of the Mineralocorticoid Receptor in the Hippocampus by Aaron M. Rozeboom A dissertation submitted in partial fulfillment of the requirements for the degree of Doctor of Philosophy (Cellular and Molecular Biology) in The University of Michigan 2008 Doctoral Committee: Professor Audrey F. Seasholtz, Chair Professor Elizabeth A. Young Professor Ronald Jay Koenig Associate Professor Gary D. Hammer Assistant Professor Jorge A. Iniguez-Lluhi Acknowledgements There are more people than I can possibly name here that I need to thank who have helped me throughout the process of writing this thesis. The first and foremost person on this list is my mentor, Audrey Seasholtz. Between working in her laboratory as a research assistant and continuing my training as a graduate student, I spent 9 years in Audrey’s laboratory and it would be no exaggeration to say that almost everything I have learned regarding scientific research has come from her. Audrey’s boundless enthusiasm, great patience, and eager desire to teach students has made my time in her laboratory a richly rewarding experience. I cannot speak of Audrey’s laboratory without also including all the past and present members, many of whom were/are not just lab-mates but also good friends. I also need to thank all the members of my committee, an amazing group of people whose scientific prowess combined with their open-mindedness allowed me to explore a wide variety of interests while maintaining intense scientific rigor. Outside of Audrey’s laboratory, there have been many people in Ann Arbor without whom I would most assuredly have gone crazy.
    [Show full text]
  • A Misplaced Lncrna Causes Brachydactyly in Humans
    A misplaced lncRNA causes brachydactyly in humans Philipp G. Maass, … , Friedrich C. Luft, Sylvia Bähring J Clin Invest. 2012;122(11):3990-4002. https://doi.org/10.1172/JCI65508. Research Article Translocations are chromosomal rearrangements that are frequently associated with a variety of disease states and developmental disorders. We identified 2 families with brachydactyly type E (BDE) resulting from different translocations affecting chromosome 12p. Both translocations caused downregulation of the parathyroid hormone-like hormone (PTHLH) gene by disrupting the cis-regulatory landscape. Using chromosome conformation capturing, we identified a regulator on chromosome 12q that interacts in cis with PTHLH over a 24.4-megabase distance and in trans with the sex- determining region Y-box 9 (SOX9) gene on chromosome 17q. The element also harbored a long noncoding RNA (lncRNA). Silencing of the lncRNA, PTHLH, or SOX9 revealed a feedback mechanism involving an expression-dependent network in humans. In the BDE patients, the human lncRNA was upregulated by the disrupted chromosomal association. Moreover, the lncRNA occupancy at the PTHLH locus was reduced. Our results document what we believe to be a novel in cis– and in trans–acting DNA and lncRNA regulatory feedback element that is reciprocally regulated by coding genes. Furthermore, our findings provide a systematic and combinatorial view of how enhancers encoding lncRNAs may affect gene expression in normal development. Find the latest version: https://jci.me/65508/pdf Research article Related Commentary, page 3837 A misplaced lncRNA causes brachydactyly in humans Philipp G. Maass,1,2 Andreas Rump,3 Herbert Schulz,2 Sigmar Stricker,4 Lisanne Schulze,1,2 Konrad Platzer,3 Atakan Aydin,1,2 Sigrid Tinschert,3 Mary B.
    [Show full text]
  • Figure S1. Representative Report Generated by the Ion Torrent System Server for Each of the KCC71 Panel Analysis and Pcafusion Analysis
    Figure S1. Representative report generated by the Ion Torrent system server for each of the KCC71 panel analysis and PCaFusion analysis. (A) Details of the run summary report followed by the alignment summary report for the KCC71 panel analysis sequencing. (B) Details of the run summary report for the PCaFusion panel analysis. A Figure S1. Continued. Representative report generated by the Ion Torrent system server for each of the KCC71 panel analysis and PCaFusion analysis. (A) Details of the run summary report followed by the alignment summary report for the KCC71 panel analysis sequencing. (B) Details of the run summary report for the PCaFusion panel analysis. B Figure S2. Comparative analysis of the variant frequency found by the KCC71 panel and calculated from publicly available cBioPortal datasets. For each of the 71 genes in the KCC71 panel, the frequency of variants was calculated as the variant number found in the examined cases. Datasets marked with different colors and sample numbers of prostate cancer are presented in the upper right. *Significantly high in the present study. Figure S3. Seven subnetworks extracted from each of seven public prostate cancer gene networks in TCNG (Table SVI). Blue dots represent genes that include initial seed genes (parent nodes), and parent‑child and child‑grandchild genes in the network. Graphical representation of node‑to‑node associations and subnetwork structures that differed among and were unique to each of the seven subnetworks. TCNG, The Cancer Network Galaxy. Figure S4. REVIGO tree map showing the predicted biological processes of prostate cancer in the Japanese. Each rectangle represents a biological function in terms of a Gene Ontology (GO) term, with the size adjusted to represent the P‑value of the GO term in the underlying GO term database.
    [Show full text]
  • ETV4 and AP1 Transcription Factors Form Multivalent Interactions with Three Sites on the MED25 Activator-Interacting Domain
    Featured Arcle KDC YJMBI-65461; No. of pages: 21; 4C: ETV4 and AP1 Transcription Factors Form Multivalent Interactions with three Sites on the MED25 Activator-Interacting Domain Simon L. Currie 1,2, Jedediah J. Doane 1,2, Kathryn S. Evans 1,2, Niraja Bhachech 1,2, Bethany J. Madison 1,2, Desmond K.W. Lau 3, Lawrence P. McIntosh 3, Jack J. Skalicky 4, Kathleen A. Clark 1,2 and Barbara J. Graves 1,2,5 1 - Department of Oncological Sciences, University of Utah School of Medicine, Salt Lake City, UT, 84112-5500, USA 2 - Huntsman Cancer Institute, University of Utah, Salt Lake City, UT, 84112-5500, USA 3 - Departments of Biochemistry and Molecular Biology, Department of Chemistry, and Michael Smith Laboratories, University of British Columbia, Vancouver, BC, V6T 1Z3, Canada 4 - Department of Biochemistry, University of Utah School of Medicine, Salt Lake City, UT, 84112-5650, USA 5 - Howard Hughes Medical Institute, Chevy Chase, MD, 20815-6789, USA Correspondence to Barbara J. Graves: Department of Oncological Sciences, University of Utah School of Medicine, Salt Lake City, UT, 84112-5500, USA. [email protected]. http://dx.doi.org/10.1016/j.jmb.2017.06.024 Edited by Prof. M.F. Summers Simon L. Currie, Jedediah J. Doane, Kathryn S. Evans and Barbara J. Graves Abstract The recruitment of transcriptional cofactors by sequence-specific transcription factors challenges the basis of high affinity and selective interactions. Extending previous studies that the N-terminal activation domain (AD) of ETV5 interacts with Mediator subunit 25 (MED25), we establish that similar, aromatic-rich motifs located both in the AD and in the DNA-binding domain (DBD) of the related ETS factor ETV4 interact with MED25.
    [Show full text]
  • Targeting Glioblastoma Stem Cells Through Disruption of the Circadian Clock
    Published OnlineFirst August 27, 2019; DOI: 10.1158/2159-8290.CD-19-0215 RESEARCH ARTICLE Targeting Glioblastoma Stem Cells through Disruption of the Circadian Clock Zhen Dong1, Guoxin Zhang1, Meng Qu2, Ryan C. Gimple1,3, Qiulian Wu1, Zhixin Qiu1, Briana C. Prager1,3, Xiuxing Wang1, Leo J.Y. Kim1,3, Andrew R. Morton3, Deobrat Dixit1, Wenchao Zhou4, Haidong Huang4, Bin Li5, Zhe Zhu1, Shideng Bao4, Stephen C. Mack6, Lukas Chavez7, Steve A. Kay2, and Jeremy N. Rich1 Downloaded from cancerdiscovery.aacrjournals.org on September 24, 2021. © 2019 American Association for Cancer Research. Published OnlineFirst August 27, 2019; DOI: 10.1158/2159-8290.CD-19-0215 ABSTRACT Glioblastomas are highly lethal cancers, containing self-renewing glioblastoma stem cells (GSC). Here, we show that GSCs, differentiated glioblastoma cells (DGC), and nonmalignant brain cultures all displayed robust circadian rhythms, yet GSCs alone displayed exquisite dependence on core clock transcription factors, BMAL1 and CLOCK, for optimal cell growth. Downregulation of BMAL1 or CLOCK in GSCs induced cell-cycle arrest and apoptosis. Chromatin immu- noprecipitation revealed that BMAL1 preferentially bound metabolic genes and was associated with active chromatin regions in GSCs compared with neural stem cells. Targeting BMAL1 or CLOCK attenu- ated mitochondrial metabolic function and reduced expression of tricarboxylic acid cycle enzymes. Small-molecule agonists of two independent BMAL1–CLOCK negative regulators, the cryptochromes and REV-ERBs, downregulated stem cell factors and reduced GSC growth. Combination of cryp- tochrome and REV-ERB agonists induced synergistic antitumor effi cacy. Collectively, these fi ndings show that GSCs co-opt circadian regulators beyond canonical circadian circuitry to promote stemness maintenance and metabolism, offering novel therapeutic paradigms.
    [Show full text]
  • 1714 Gene Comprehensive Cancer Panel Enriched for Clinically Actionable Genes with Additional Biologically Relevant Genes 400-500X Average Coverage on Tumor
    xO GENE PANEL 1714 gene comprehensive cancer panel enriched for clinically actionable genes with additional biologically relevant genes 400-500x average coverage on tumor Genes A-C Genes D-F Genes G-I Genes J-L AATK ATAD2B BTG1 CDH7 CREM DACH1 EPHA1 FES G6PC3 HGF IL18RAP JADE1 LMO1 ABCA1 ATF1 BTG2 CDK1 CRHR1 DACH2 EPHA2 FEV G6PD HIF1A IL1R1 JAK1 LMO2 ABCB1 ATM BTG3 CDK10 CRK DAXX EPHA3 FGF1 GAB1 HIF1AN IL1R2 JAK2 LMO7 ABCB11 ATR BTK CDK11A CRKL DBH EPHA4 FGF10 GAB2 HIST1H1E IL1RAP JAK3 LMTK2 ABCB4 ATRX BTRC CDK11B CRLF2 DCC EPHA5 FGF11 GABPA HIST1H3B IL20RA JARID2 LMTK3 ABCC1 AURKA BUB1 CDK12 CRTC1 DCUN1D1 EPHA6 FGF12 GALNT12 HIST1H4E IL20RB JAZF1 LPHN2 ABCC2 AURKB BUB1B CDK13 CRTC2 DCUN1D2 EPHA7 FGF13 GATA1 HLA-A IL21R JMJD1C LPHN3 ABCG1 AURKC BUB3 CDK14 CRTC3 DDB2 EPHA8 FGF14 GATA2 HLA-B IL22RA1 JMJD4 LPP ABCG2 AXIN1 C11orf30 CDK15 CSF1 DDIT3 EPHB1 FGF16 GATA3 HLF IL22RA2 JMJD6 LRP1B ABI1 AXIN2 CACNA1C CDK16 CSF1R DDR1 EPHB2 FGF17 GATA5 HLTF IL23R JMJD7 LRP5 ABL1 AXL CACNA1S CDK17 CSF2RA DDR2 EPHB3 FGF18 GATA6 HMGA1 IL2RA JMJD8 LRP6 ABL2 B2M CACNB2 CDK18 CSF2RB DDX3X EPHB4 FGF19 GDNF HMGA2 IL2RB JUN LRRK2 ACE BABAM1 CADM2 CDK19 CSF3R DDX5 EPHB6 FGF2 GFI1 HMGCR IL2RG JUNB LSM1 ACSL6 BACH1 CALR CDK2 CSK DDX6 EPOR FGF20 GFI1B HNF1A IL3 JUND LTK ACTA2 BACH2 CAMTA1 CDK20 CSNK1D DEK ERBB2 FGF21 GFRA4 HNF1B IL3RA JUP LYL1 ACTC1 BAG4 CAPRIN2 CDK3 CSNK1E DHFR ERBB3 FGF22 GGCX HNRNPA3 IL4R KAT2A LYN ACVR1 BAI3 CARD10 CDK4 CTCF DHH ERBB4 FGF23 GHR HOXA10 IL5RA KAT2B LZTR1 ACVR1B BAP1 CARD11 CDK5 CTCFL DIAPH1 ERCC1 FGF3 GID4 HOXA11 IL6R KAT5 ACVR2A
    [Show full text]
  • Reversal of Glucocorticoid Resistance in Paediatric Acute Lymphoblastic Leukaemia Is Dependent on Restoring BIM Expression
    www.nature.com/bjc ARTICLE Translational Therapeutics Reversal of glucocorticoid resistance in paediatric acute lymphoblastic leukaemia is dependent on restoring BIM expression Cara E. Toscan1, Duohui Jing1, Chelsea Mayoh1 and Richard B. Lock1 BACKGROUND: Acute lymphoblastic leukaemia (ALL) is the most common paediatric malignancy. Glucocorticoids form a critical component of chemotherapy regimens and resistance to glucocorticoid therapy is predictive of poor outcome. We have previously shown that glucocorticoid resistance is associated with upregulation of the oncogene C-MYC and failure to induce the proapoptotic gene BIM. METHODS: A high-throughput screening (HTS) campaign was carried out to identify glucocorticoid sensitisers against an ALL xenograft derived from a glucocorticoid-resistant paediatric patient. Gene expression analysis was carried out using Illumina microarrays. Efficacy, messenger RNA and protein analysis were carried out by Resazurin assay, reverse transcription-PCR and immunoblotting, respectively. RESULTS: A novel glucocorticoid sensitiser, 2-((4,5-dihydro-1H-imidazol-2-yl)thio)-N-isopropyl-N-phenylacetamide (GCS-3), was identified from the HTS campaign. The sensitising effect was specific to glucocorticoids and synergy was observed in a range of dexamethasone-resistant and dexamethasone-sensitive xenografts representative of B-ALL, T-ALL and Philadelphia chromosome- positive ALL. GCS-3 in combination with dexamethasone downregulated C-MYC and significantly upregulated BIM expression in a glucocorticoid-resistant ALL xenograft. The GCS-3/dexamethasone combination significantly increased binding of the glucocorticoid receptor to a novel BIM enhancer, which is associated with glucocorticoid sensitivity. CONCLUSIONS: This study describes the potential of the novel glucocorticoid sensitiser, GCS-3, as a biological tool to interrogate glucocorticoid action and resistance.
    [Show full text]
  • Curcumin Alters Gene Expression-Associated DNA Damage, Cell Cycle, Cell Survival and Cell Migration and Invasion in NCI-H460 Human Lung Cancer Cells in Vitro
    ONCOLOGY REPORTS 34: 1853-1874, 2015 Curcumin alters gene expression-associated DNA damage, cell cycle, cell survival and cell migration and invasion in NCI-H460 human lung cancer cells in vitro I-TSANG CHIANG1,2, WEI-SHU WANG3, HSIN-CHUNG LIU4, SU-TSO YANG5, NOU-YING TANG6 and JING-GUNG CHUNG4,7 1Department of Radiation Oncology, National Yang‑Ming University Hospital, Yilan 260; 2Department of Radiological Technology, Central Taiwan University of Science and Technology, Taichung 40601; 3Department of Internal Medicine, National Yang‑Ming University Hospital, Yilan 260; 4Department of Biological Science and Technology, China Medical University, Taichung 404; 5Department of Radiology, China Medical University Hospital, Taichung 404; 6Graduate Institute of Chinese Medicine, China Medical University, Taichung 404; 7Department of Biotechnology, Asia University, Taichung 404, Taiwan, R.O.C. Received March 31, 2015; Accepted June 26, 2015 DOI: 10.3892/or.2015.4159 Abstract. Lung cancer is the most common cause of cancer CARD6, ID1 and ID2 genes, associated with cell survival and mortality and new cases are on the increase worldwide. the BRMS1L, associated with cell migration and invasion. However, the treatment of lung cancer remains unsatisfactory. Additionally, 59 downregulated genes exhibited a >4-fold Curcumin has been shown to induce cell death in many human change, including the DDIT3 gene, associated with DNA cancer cells, including human lung cancer cells. However, the damage; while 97 genes had a >3- to 4-fold change including the effects of curcumin on genetic mechanisms associated with DDIT4 gene, associated with DNA damage; the CCPG1 gene, these actions remain unclear. Curcumin (2 µM) was added associated with cell cycle and 321 genes with a >2- to 3-fold to NCI-H460 human lung cancer cells and the cells were including the GADD45A and CGREF1 genes, associated with incubated for 24 h.
    [Show full text]
  • ETV4 Collaborates with Wnt/Β-Catenin Signaling to Alter Cell Cycle Activity and Promote Tumor Aggressiveness in Gastrointestinal Stromal Tumor
    www.impactjournals.com/oncotarget/ Oncotarget, 2017, Vol. 8, (No. 69), pp: 114195-114209 Research Paper ETV4 collaborates with Wnt/β-catenin signaling to alter cell cycle activity and promote tumor aggressiveness in gastrointestinal stromal tumor Shan Zeng1, Adrian M. Seifert1, Jennifer Q. Zhang1, Teresa S. Kim1, Timothy G. Bowler2, Michael J. Cavnar1, Benjamin D. Medina1, Gerardo A. Vitiello1, Ferdinand Rossi1, Jennifer K. Loo1, Nesteene J. Param1 and Ronald P. DeMatteo1 1Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA 2Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA Correspondence to: Ronald P. DeMatteo, email: [email protected] Keywords: gastrointestinal stromal tumor; ETV4; Wnt/β-catenin signaling Received: August 30, 2017 Accepted: November 26, 2017 Published: December 11, 2017 Copyright: Zeng et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License 3.0 (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. ABSTRACT Gastrointestinal stromal tumor (GIST) is the most common sarcoma, often resulting from a KIT or platelet-derived growth factor receptor alpha (PDGFRA) mutation. The lineage transcription factor ETV1 is expressed similarly in GISTs regardless of malignant potential. Although the related transcription factor ETV4 has been associated with metastasis and tumor progression in other cancers, its role in GIST is unknown. In this study, we found that ETV4 levels were high in a subset of human GISTs and correlated with high mitotic rate. Through Gene Set Enrichment Analysis in selected human GISTs, we identified a relationship between ETV4 levels and β-catenin signaling, especially in advanced GISTs.
    [Show full text]
  • The Human CRY1 Tail Controls Circadian Timing by Regulating Its Association with CLOCK:BMAL1
    The human CRY1 tail controls circadian timing by regulating its association with CLOCK:BMAL1 Gian Carlo G. Paricoa, Ivette Pereza, Jennifer L. Fribourgha, Britney N. Hernandeza, Hsiau-Wei Leea, and Carrie L. Partcha,b,1 aDepartment of Chemistry and Biochemistry, University of California, Santa Cruz, CA 95064; and bCenter for Circadian Biology, University of California San Diego, La Jolla, CA 92093 Edited by Joseph S. Takahashi, The University of Texas Southwestern Medical Center, Dallas, TX, and approved September 29, 2020 (received for review November 22, 2019) Circadian rhythms are generated by interlocked transcription– disordered C-terminal tail of CRY1. While only the PHR do- translation feedback loops that establish cell-autonomous biolog- main of CRY1 is necessary to reconstitute circadian rhythms in −/− −/− Luc ical timing of ∼24 h. Mutations in core clock genes that alter their Cry1 ;Cry2 ;Per2 cells (15), the tails can modulate the stability or affinity for one another lead to changes in circadian period and/or amplitude of cycling, as evidenced by reconstitu- period. The human CRY1Δ11 mutant lengthens circadian period to tion assays using chimeras swapping the CRY1 and CRY2 tails cause delayed sleep phase disorder (DSPD), characterized by a very (15–17) or assessing posttranslational modifications like phos- late onset of sleep. CRY1 is a repressor that binds to the transcrip- phorylation in the tail (18–20). Mechanistically, the CRY1 PHR tion factor CLOCK:BMAL1 to inhibit its activity and close the core binds directly to both CLOCK (3, 21) and BMAL1 (4, 5, 22) feedback loop. We previously showed how the PHR (photolyase subunits as well as the CRY-binding domain (CBD) of PER2 homology region) domain of CRY1 interacts with distinct sites on (23) to form the central linchpin of vertebrate circadian re- CLOCK and BMAL1 to sequester the transactivation domain from pressive complexes (24).
    [Show full text]
  • The Tumor Suppressor CIC Directly Regulates MAPK Pathway Genes Via Histone Deacetylation Simon Weissmann1,2, Paul A
    Published OnlineFirst May 29, 2018; DOI: 10.1158/0008-5472.CAN-18-0342 Cancer Genome and Epigenome Research The Tumor Suppressor CIC Directly Regulates MAPK Pathway Genes via Histone Deacetylation Simon Weissmann1,2, Paul A. Cloos1,2, Simone Sidoli2,3, Ole N. Jensen2,3, Steven Pollard4, and Kristian Helin1,2,5 Abstract Oligodendrogliomas are brain tumors accounting for approximately 10% of all central nervous system can- Low MAPK signaling High MAPK signaling cers. CIC is a transcription factor that is mutated in most RTKs patients with oligodendrogliomas; these mutations are believed to be a key oncogenic event in such cancers. MEK Analysis of the Drosophila melanogaster ortholog of ERK SIN3 CIC, Capicua, indicates that CIC loss phenocopies CIC HDAC activation of the EGFR/RAS/MAPK pathway, and HMG C-term studies in mammalian cells have demonstrated a role SIN3 CIC HDAC for CIC in repressing the transcription of the PEA3 HMG C-term Ac Ac subfamily of ETS transcription factors. Here, we address Ac Ac the mechanism by which CIC represses transcription and assess the functional consequences of CIC inacti- vation. Genome-wide binding patterns of CIC in several cell types revealed that CIC target genes were enriched ETV, DUSP, CCND1/2, SHC3,... for MAPK effector genes involved in cell-cycle regulation Normal Astrocytoma and proliferation. CIC binding to target genes was Glioblastoma multiforme abolished by high MAPK activity, which led to their 1p/19q deletion CIC-Mutants transcriptional activation. CIC interacted with the SIN3 SIN3 deacetylation complex and, based on our results, we SIN3 CIC suggest that CIC functions as a transcriptional repressor HDAC HDAC HMG C-term through the recruitment of histone deacetylases.
    [Show full text]
  • Netfactor, a Framework for Identifying Transcriptional Regulators of Gene
    www.nature.com/scientificreports OPEN NeTFactor, a framework for identifying transcriptional regulators of gene expression- Received: 31 December 2018 Accepted: 27 August 2019 based biomarkers Published: xx xx xxxx Mehmet Eren Ahsen 1, Yoojin Chun1, Alexander Grishin2, Galina Grishina2, Gustavo Stolovitzky 1,3, Gaurav Pandey 1 & Supinda Bunyavanich 1,2 Biological and regulatory mechanisms underlying many multi-gene expression-based disease biomarkers are often not readily evident. We describe an innovative framework, NeTFactor, that combines network analyses with gene expression data to identify transcription factors (TFs) that signifcantly and maximally regulate such a biomarker. NeTFactor uses a computationally-inferred context-specifc gene regulatory network and applies topological, statistical, and optimization methods to identify regulator TFs. Application of NeTFactor to a multi-gene expression-based asthma biomarker identifed ETS translocation variant 4 (ETV4) and peroxisome proliferator-activated receptor gamma (PPARG) as the biomarker’s most signifcant TF regulators. siRNA-based knock down of these TFs in an airway epithelial cell line model demonstrated signifcant reduction of cytokine expression relevant to asthma, validating NeTFactor’s top-scoring fndings. While PPARG has been associated with airway infammation, ETV4 has not yet been implicated in asthma, thus indicating the possibility of novel, disease-relevant discovery by NeTFactor. We also show that NeTFactor’s results are robust when the gene regulatory network and biomarker are derived from independent data. Additionally, our application of NeTFactor to a diferent disease biomarker identifed TF regulators of interest. These results illustrate that the application of NeTFactor to multi-gene expression-based biomarkers could yield valuable insights into regulatory mechanisms and biological processes underlying disease.
    [Show full text]